--- title: "Zymeworks (ZYME) news: merger and buyback" url: "https://aibio.space/companies/zymeworks/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ZYME merger and buyback news: Zymeworks agrees to buy Theravance Biopharma for $17 per share, about $929 million. Zymeworks Inc." --- ZYME Zymeworks Inc. NASDAQ · United States # Zymeworks (ZYME) news ZYME merger and buyback news Mergers · 2026-09-23 ## [Zymeworks completes Theravance Biopharma acquisition, with $350 million in senior secured notes](https://aibio.space/news/zymeworks-completes-theravance-biopharma-acquisition-350-million/) Zymeworks subsidiaries sold $350,000,000 of 8.25% senior secured notes due December 31, 2036 to an OMERS Private Capital affiliate, and former Theravance holders received contingent value rights that the filing calls highly speculative. ## Latest Zymeworks news 1. 2026-06-29 Mergers [Zymeworks agrees to buy Theravance Biopharma for $17 per share, about $929 million](https://aibio.space/news/zymeworks-agrees-buy-theravance-biopharma-17-share-about-929-million/) Zymeworks will pay $17.00 per share in cash, financed mainly by a $350 million non-recourse note from OMERS Life Sciences. The release says 75% of the YUPELRI profit-share cash flows are assigned to OMERS to service the note. 2. 2026-05-14 Financings [Zymeworks authorizes $125.0 million share repurchase program, ends 2025 program](https://aibio.space/news/zymeworks-authorizes-125-0-million-share-repurchase-program-ends-2025/) The earlier program bought back shares at an average price of $24.36 for $102.3 million. Zymeworks had about 73.0 million common shares outstanding as of May 13, 2026. 3. 2026-03-02 Financings [Zymeworks enters $250 million royalty-backed financing with Royalty Pharma](https://aibio.space/news/zymeworks-enters-250-million-royalty-backed-financing-royalty-pharma/) Zymeworks sold 30% of its future Ziihera royalties to a subsidiary that borrowed $250 million from Royalty Pharma. The loan costs about $481 million by its 2042 maturity, and it is secured by the subsidiary's assets. 4. 2025-06-27 Financings [Zymeworks issues 5,086,480 shares as EcoR1 funds exercise pre-funded warrants](https://aibio.space/news/zymeworks-issues-5-086-480-shares-ecor1-funds-exercise-pre-funded/) The warrant holders net exercised in full after Zymeworks removed a 19.99% ownership cap. Shares outstanding rose to 74,844,505. ## Zymeworks at a glance - **Ticker**: ZYME - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $179.4 million ### Related companies - [MannKind](https://aibio.space/companies/mannkind/) NASDAQ: MNKD - [Harrow](https://aibio.space/companies/harrow/) NASDAQ: HROW - [Nano Mobile Healthcare](https://aibio.space/companies/nano-mobile-healthcare/) OTC: VNTH - [aTyr Pharma](https://aibio.space/companies/atyr-pharma/) NASDAQ: ATYR - [Artelo Biosciences](https://aibio.space/companies/artelo-biosciences/) NASDAQ: ARTL - [Nektar Therapeutics](https://aibio.space/companies/nektar-therapeutics/) NASDAQ: NKTR - [Evolus](https://aibio.space/companies/evolus/) NASDAQ: EOLS - [AIM ImmunoTech](https://aibio.space/companies/aim-immunotech/) AMEX: AIM ### Also on NASDAQ - [MediciNova](https://aibio.space/companies/medicinova/) MNOV - [Lisata Therapeutics](https://aibio.space/companies/lisata-therapeutics/) LSTA - [REPLIGEN CORP](https://aibio.space/companies/repligen/) RGEN - [iBio](https://aibio.space/companies/ibio/) IBIO - [Mirum Pharmaceuticals](https://aibio.space/companies/mirum-pharmaceuticals/) MIRM - [Vivani Medical](https://aibio.space/companies/vivani-medical/) VANI ## What Zymeworks does Zymeworks is a company that uses protein engineering and drug chemistry to discover and develop next-generation antibody-based therapeutics for hard-to-treat diseases. Its structure-guided molecular modeling, combined with internal antibody discovery and generation technologies, supports an integrated drug development engine. Its pipeline of multifunctional therapeutics is built on multispecific antibody therapeutics (MSATs) and antibody-drug conjugates (ADCs) platforms, aimed at cancer, inflammation and autoimmune disease. Partnerships and collaborations are central to its strategy, as a source of funding for research and development and to share risk, particularly in late-stage development. Through an asset and royalty aggregation strategy, Zymeworks seeks to optimize future cash flows from a growing portfolio of licensed products and product candidates, including Ziihera (zanidatamab-hrii) and pasritamig. As its royalty portfolio matures and generates capital beyond the needs of its operations and strategic investments, the company may allocate capital to stock repurchases. | Product or program | What it is | Stage | |---|---|---| | Ziihera (zanidatamab-hrii) | Licensed product in Zymeworks' royalty portfolio | | | Pasritamig | Licensed product or candidate in Zymeworks' royalty portfolio | | Summarised from the company's [10-K filed Mar 2, 2026](https://www.sec.gov/Archives/edgar/data/1937653/000193765326000015/zyme-20251231.htm). ## Zymeworks annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$106.0 million](https://www.sec.gov/Archives/edgar/data/1937653/000193765326000015/) | [$76.3 million](https://www.sec.gov/Archives/edgar/data/1937653/000193765326000015/) | | Net income (loss) | [-$81.1 million](https://www.sec.gov/Archives/edgar/data/1937653/000193765326000015/) | [-$122.7 million](https://www.sec.gov/Archives/edgar/data/1937653/000193765326000015/) | | Cash from operations | [-$33.0 million](https://www.sec.gov/Archives/edgar/data/1937653/000193765326000015/) | [-$110.1 million](https://www.sec.gov/Archives/edgar/data/1937653/000193765326000015/) | | Cash and equivalents | [$41.2 million](https://www.sec.gov/Archives/edgar/data/1937653/000193765326000047/) | [$66.1 million](https://www.sec.gov/Archives/edgar/data/1937653/000193765326000015/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $179.4 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Zymeworks Is Zymeworks involved in a merger or acquisition? Our latest story on this, dated Jun 29, 2026: "Zymeworks agrees to buy Theravance Biopharma for $17 per share, about $929 million". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/zymeworks-agrees-buy-theravance-biopharma-17-share-about-929-million/). Does Zymeworks have a share buyback? Our latest story on this, dated May 14, 2026: "Zymeworks authorizes $125.0 million share repurchase program, ends 2025 program". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/zymeworks-authorizes-125-0-million-share-repurchase-program-ends-2025/). What is the ticker symbol of Zymeworks? Zymeworks Inc. trades under the ticker ZYME on NASDAQ. Where is Zymeworks listed? Zymeworks Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:ZA8. What is the SEC CIK of Zymeworks? The SEC Central Index Key (CIK) for Zymeworks Inc. is 1937653. Its filings are on SEC EDGAR. How many shares does Zymeworks have outstanding? 70,959,241 shares as of 2026-08-04, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is Zymeworks listed under? Our directory records Zymeworks Inc. under United States. What does Zymeworks do? Our directory classifies Zymeworks Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Zymeworks? The ISIN recorded for Zymeworks Inc. is US98985Y1082. Does aibio.space cover Zymeworks? aibio.space lists Zymeworks Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Zymeworks incorporated? SEC records list its state or country of incorporation as DE. What does Zymeworks develop? Zymeworks is a company that uses protein engineering and drug chemistry to discover and develop next-generation antibody-based therapeutics for hard-to-treat diseases. Its structure-guided molecular modeling, combined with internal antibody discovery and generation technologies, supports an integrated drug development engine. What is Ziihera (zanidatamab-hrii) from Zymeworks? Ziihera (zanidatamab-hrii): Licensed product in Zymeworks' royalty portfolio What is Pasritamig from Zymeworks? Pasritamig: Licensed product or candidate in Zymeworks' royalty portfolio What was Zymeworks's revenue last year? $106.0 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. ## Investor discussion: Zymeworks Members talk about Zymeworks (ZYME). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Zymeworks, newest first. Each line links the filing it comes from. 1. 2026-06-29 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1937653/000119312526286829/d156494dex991.htm) 2. 2026-05-14 Financings Announced a share repurchase program. SEC Form 8-K (Items 7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1937653/000119312526224161/d110930dex991.htm) 3. 2025-11-18 Financings Announced a share repurchase program. SEC Form 8-K (Items 5.02,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1937653/000119312525285259/d851143dex991.htm) 4. 2025-06-27 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1937653/000119312525151279/d19414d8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ZYME on TradingView](https://www.tradingview.com/symbols/NASDAQ-ZYME/). ## SEC filings and registration - **SEC name**: Zymeworks Inc. - **CIK**: 1937653 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: ZYME (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 108 PATRIOT DRIVE, SUITE A, MIDDLETOWN, DE, 19709 - **Phone**: 302-274-8744 - **Shares outstanding**: 70,959,241 as of 2026-08-04 (10-Q filed 2026-08-06) - **Former names**: Zymeworks Delaware Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1937653/000119312526399383/d270232d8k.htm) filed 2026-09-23 - [8-K](https://www.sec.gov/Archives/edgar/data/1937653/000193765326000051/zyme-20260825.htm) filed 2026-08-25 - [10-Q](https://www.sec.gov/Archives/edgar/data/1937653/000193765326000047/zyme-20260630.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1937653/000193765326000046/zyme-20260806.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1937653/000119312526286829/d156494d8k.htm) filed 2026-06-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1937653/000119312526224161/d110930d8k.htm) filed 2026-05-14 - [10-Q](https://www.sec.gov/Archives/edgar/data/1937653/000193765326000034/zyme-20260331.htm) filed 2026-05-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1937653/000193765326000033/zyme-20260507.htm) filed 2026-05-07 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001937653), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Zymeworks Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ZYME, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Zymeworks Inc. - **Ticker**: ZYME - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US98985Y1082 - **Other listed symbols**: GETTEX:ZA8 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ZYME/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/zymeworks/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Zymeworks (ZYME) news: merger and buyback", 2026-10-31, https://aibio.space/companies/zymeworks/